ZCL278

CAS No. 587841-73-4

ZCL278( ZCL 278 | ZCL-278 )

Catalog No. M15167 CAS No. 587841-73-4

A potent, cell-permeable Cdc42-specific small-molecule inhibitor (Kd=6.4 uM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 41 In Stock
10MG 65 In Stock
25MG 124 In Stock
50MG 210 In Stock
100MG 294 In Stock
200MG 471 In Stock
500MG 763 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ZCL278
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, cell-permeable Cdc42-specific small-molecule inhibitor (Kd=6.4 uM).
  • Description
    A potent, cell-permeable Cdc42-specific small-molecule inhibitor (Kd=6.4 uM); specifically targets Cdc42–intersectin interaction and inhibits Cdc42-mediated cellular processes, including Golgi organization and cell motility.
  • In Vitro
    ZCL278 as a potent, cell-permeable Cdc42-specific inhibitor that suppresses actin-based cellular functions, including Golgi organization and cell motility.In Swiss 3T3 fibroblast cultures, ZCL278 abolishes microspike formation and disrupted GM130-docked Golgi structures, two of the most prominent Cdc42-mediated subcellular events. ZCL278 reduces the perinuclear accumulation of active Cdc42 in contrast to NSC23766, a selective Rac inhibitor. ZCL278 suppresses Cdc42-mediated neuronal branching and growth cone dynamics as well as actin-based motility and migration in a metastatic prostate cancer cell line (i.e., PC-3) without disrupting cell viability. ZCL278 inhibits Cdc42 function as an entry inhibitor for Junin virus (JUNV) and for vesicular stomatitis virus, lymphocytic choriomeningitis virus, and dengue virus but not for the nonenveloped poliovirus. In cells, ZCL278 is shown to efficiently inhibit chemically induced filopodium formation, a process dependent on Cdc42 activity. Dose-response experiments are first carried out in Vero cells, and while ZCL278 is not toxic at concentrations up to 200 μM, ZCL278 inhibits JUNV with IC50 of ~14 μM, as measured by flow cytometry.
  • In Vivo
    ZCL278 reduces the JUNV RNA load in the spleen more than 33-fold, with JUNV RNA being undetectable in 5 out of 8 mice. These results are similar to those seen in Gabapentin-treated mice, demonstrating that ZCL278 can abrogate JUNV replication.
  • Synonyms
    ZCL 278 | ZCL-278
  • Pathway
    MAPK/ERK Signaling
  • Target
    Ras
  • Recptor
    Cdc42GTPase
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    587841-73-4
  • Formula Weight
    584.8937
  • Molecular Formula
    C21H19BrClN5O4S2
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    O=C(NC(NC1=CC=C(S(=O)(NC2=NC(C)=CC(C)=N2)=O)C=C1)=S)COC3=CC=C(Br)C=C3Cl
  • Chemical Name
    Acetamide, 2-(4-bromo-2-chlorophenoxy)-N-[[[4-[[(4,6-dimethyl-2-pyrimidinyl)amino]sulfonyl]phenyl]amino]thioxomethyl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Friesland A, et al. Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1261-6. 2. Liu X, et al. Cell Physiol Biochem. 2015;36(4):1613-27.
molnova catalog
related products
  • KRAS inhibitor-9

    KRAS inhibitor-9 is a potent KRAS inhibitor with Kd of 92 μM that blocks the formation of GTP-KRAS and downstream activation of KRAS.?

  • J-104871

    J-104871 (UNII-6137X5QNJF) is a novel farnesyltransferase (FTase) inhibitor that competitively blocks Ras farnesylation in vivo, inhibits Ras processing in activated H-ras-transformed NIH3T3 cells, and suppresses tumor growth in nude mice transplanted with activated H-ras-transformed NIH3T3 cells.

  • (S)-BAY-293

    (S)-BAY-293 (BAY293 S-enantiomer) is the S-enantiomer of BAY-293 as a negative control compound.